Rhumbline Advisers Has $2.41 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Rhumbline Advisers boosted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,815 shares of the medical device company’s stock after buying an additional 8,050 shares during the period. Rhumbline Advisers owned about 0.16% of AtriCure worth $2,409,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Arcadia Investment Management Corp MI acquired a new position in shares of AtriCure in the 3rd quarter valued at about $28,000. Heck Capital Advisors LLC acquired a new position in shares of AtriCure in the 4th quarter valued at about $60,000. KBC Group NV increased its holdings in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after purchasing an additional 932 shares during the period. R Squared Ltd acquired a new position in shares of AtriCure in the 4th quarter valued at about $89,000. Finally, Silver Oak Securities Incorporated acquired a new position in shares of AtriCure in the 4th quarter valued at about $220,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ATRC shares. Piper Sandler upped their target price on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Canaccord Genuity Group upped their target price on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Needham & Company LLC reiterated a “buy” rating and issued a $51.00 target price on shares of AtriCure in a report on Thursday, February 13th. Stifel Nicolaus increased their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price objective on AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.56.

AtriCure Stock Up 0.6 %

Shares of AtriCure stock opened at $38.74 on Monday. The stock has a market capitalization of $1.89 billion, a P/E ratio of -40.78 and a beta of 1.46. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $37.19 and a two-hundred day moving average price of $32.67. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.